- Home
- SITC vs PALI Comparison
SITC vs PALI Comparison
Compare SITC & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$5.40
HOLD
Current Price
$1.90
Company Overview
Basic Information| Metric | SITC | PALI |
|---|---|---|
| Founded | 1965 | 1996 |
| Country | United States | United States |
| Employees | 155 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.5M | 240.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SITC | PALI |
|---|---|---|
| Price | $5.40 | $1.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $7.75 | ★ $12.00 |
| AVG Volume (30 Days) | 989.7K | ★ 3.9M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | ★ 125.00% | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.09 | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $5.24 | $0.55 |
| 52 Week High | $12.74 | $2.64 |
Technical Indicators
Market Signals| Indicator | SITC | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 50.99 |
| Support Level | N/A | $1.58 |
| Resistance Level | $6.57 | $2.05 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 27.59 | 60.29 |
Price Performance
Historical Comparison SITC
PALI
About SITC SITE Centers Corp.
SITE Centers Corp is a self-administered and self-managed REIT that operates as a fully integrated real estate company. The company is engaged in the business of owning, leasing, acquiring, redeveloping, developing, and managing shopping centers.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.